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Bayesian detection of abnormal hematological
values to introduce a no-start rule  for
heterogeneous populations of athletes
Sports authorities exclude athletes with abnor-
mal levels of blood parameters. Here, the consider-
ation of longitudinal blood profiles together with
heterogeneous factors such as ethnicity and age
produces a model with enhanced sensitivity to
detect blood doping. Sports disciplines with het-
erogeneous populations now have a general
method to introduce the no-start rule.
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In sports, rHuEPO, the recombinant form of erythro-
poietin, is illicitly used to improve physical performance.
Some sports federations with a fairly homogeneous pop-
ulation of athletes have discouraged rHuEPO doping by
introducing hematocrit (Hct) and hemoglobin (Hb) limits.
Athletes tested above these limits are declared unfit for
competition: the so-called no-start rule. Unfortunately,
since Hct and Hb present elevated between-subject vari-
ations1 and can easily be manipulated,2 the efficiency of
both variables remains limited. Models using multiple
hematological variables, such as Abnormal Blood Profile
Score (ABPS),3 were proposed to improve
sensitivity/specificity. Along with this, the idea of a
hematological passport was also suggested.4 Sportsmen
with significant differences between new test results and
an individual historical baseline could be excluded from
competition.1
Hematological variables depend on various factors
such as gender, ethnicity and age. Even though the effects
of these factors on hematological parameters have been
well described,5 they have not been taken into consider-
ation in the formulation of a blood model. This leads to
an unpredictable number of false-positive findings for
heterogeneous populations. Unsurprisingly, sports feder-
ations with highly heterogeneous populations refrained
from introducing a no-start rule. 
We, therefore, propose a blood test that combines a
multiparametric approach for increased specificity, a
hematological passport for individual longitudinal moni-
toring, and the formal integration of various factors for
heterogeneous populations. The blood test is based on a
global Bayesian inference approach for the detection of
abnormal values over time.6 Hb and ABPS3 (with Hct,
Hb, RBC count, reticulocytes percentage, mean corpuscu-
lar volume, mean corpuscular Hb, mean corpuscular Hb
concentration variables) markers are used. Effects of gen-
der [male, female], ethnicity [Caucasian, Asian, African,
Oceanian], age [<19 years, 19-24 years, >24 years], alti-
tude [<610, 610-1730, >1730], sport [endurance, non-
endurance] on the mean of each parameter were taken
from published data.5 Except for gender, the variance of
blood parameters is considered independent of the fac-
tors and modeled as a log-normal distribution with
parameters estimated from data collected on control sub-
jects. Firstly, 135 blood profiles were collected from 22
top-level elite endurance athletes, 11 males and 11
females, participating in a study commissioned by the
Swiss Federal Office for Sport to promote drug-free
sports. Regular anti-doping tests were conducted on each
athlete over a period of 2 years (6 blood and 11 urine
samples in average) returning only negative test results.
Secondly, 572 blood profiles were collected from 47 male
amateur athletes over a period of two months (347 with
an Advia 120, Bayer Diagnostics, Zurich, Switzerland,
225 with a XT-2000i analyzer, Sysmex, Norderstedt,
Germany). Sensitivity was estimated from data collected
in a two month rHuEPO clinical trial described else-
where.3,7 To summarized, 32 healthy volunteer males par-
ticipated in this study. The aim was to reproduce rHuEPO
doping habits practised in some sports. Eight subjects
received subcutaneous injections of 40 IU/kg of EPREX
three times a week (group R40), 8 subjects 80 IU/kg doses
(group R80), 8 subjects received placebo (group P),  and
the last 8 subjects (group NT) had no treatment. rHuEPO
administration in R40 and R80 groups was nevertheless
individualized. A full dosage was administered for Hct
below 45%, half doses for Hct between 45 and 50%, and
substitution by isotonic saline when Hct exceeded 50%.
Five hundred and ten blood samples (178 from doped
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Figure 1. A. Red line represents the limits
found for a specificity of 99.9% for the female
subject. The first value at 168 g/L represents a
population threshold: 1 in 1,000 28 year old
female Caucasian endurance athletes living at
low altitude should in average present a value
higher than 168. The cut-off limit changes as
soon as individual Hb values (blue data) are
taken into account. In case of a very high num-
ber of individual test results, the last value,
here 142, represents an individual limit inde-
pendent of any population factor. B. Red line
represents the limits for the male subject.
Information about his location was not avail-
able. Black line represents limits, however,
including the information that all tests were
conducted at low altitude, except for the 4th, 5th
and 7th tests which were conducted above
2,000 meters. Interestingly, the final cut-off
limit was lower when an altitude model was
explicitly considered (171 vs 182) i.e. a higher
sensitivity to blood doping. Likewise, thresholds
were higher when the athlete is tested in high
altitude (e.g. 189 vs 175 for the 4th test) i.e. a
lower probability of a false-positive.
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subjects) were analyzed on a Cell-Dyn 4000 instrument
(Abbott Diagnostics Division, Baar, Switzerland). In total,
1,039 samples collected in the three studies were used to
estimate the specificity.  For didactic purposes, we
applied the Bayesian model to two subjects (Figure 1).
The first subject is a top-level female Caucasian
endurance athlete, 28 years old, living at low altitude.
The second subject is a top-level male African endurance
athlete, 36 years old, living and training occasionally at
high altitude. Consideration of a new individual Hb value
induces a new distribution of possible values of Hb, and,
therefore, new individual reference range. The significant
decrease between the first (a population-based threshold)
and the last cut-off limit (an individual threshold) can be
associated to a larger between- than within-subject vari-
ance of the hematological variable.1,6,8
All three aspects of the model, multiparametric
approach, longitudinal analysis and consideration of het-
erogeneous factors, lead to a decrease of the overall vari-
ance of hematological data. As shown in Table 1, a
heightened sensitivity to discontinuous rHuEPO treat-
ment was observed. A population-based strategy on Hb
gives only 3 true positives for a specificity of 0.999,
whereas the Bayesian model returned as much as 11
times more true positives. With the ABPS marker, sensi-
tivity was even further improved.
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Table 1. Sensitivity and specificity of the model based on 1,217
samples for selected false-positive rates (FPR) of 1/100 and
1/1,000. Second line is the 95% interval of the expected number
of false-positive findings. 
FPR FPR
1/100 1/1,000
95% expected 5-17 0-3
Specificity
(1,039 samples)
Hb
Pop 17 (1.6%) 1 (0.10%)
BN 11 (1.06%) 2 (0.19%)
ABPS
Pop 8 (0.77%) 1 (0.10%)
BN 10 (0.96%) 2 (0.19%)
rHuEPO sensitivity
(178 samples)
Hb
Pop 18 (10%) 3 (1.7%)
BN 59 (33%) 33 (19%)
ABPS
Pop 78 (44%) 55 (31%)
BN 119 (67%) 102 (57%)
Number of samples and the corresponding percentage are either given for a
population limit (pop)5 or the Bayesian model (BN), for hemoglobin (Hb)
and the multiparametric Abnormal Blood Profile Score (ABPS)3 model. 
